Clinical trial NCT03984552: Validation of Rapid Tests for the Serological Diagnosis of HIV in 9 to 24 Months Old Children
Official title: Validation of Rapid Tests for the Serological Diagnosis of HIV in 9 to 24 Months Old Children
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Human Immunodeficiency Virus Transmission
Human Immunodeficiency Virus
Diagnoses, Syndromes, and Conditions
Keywords: HIV
rapid test
HIV infection
vertical transmission
Lead sponsor: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Sponsor class: OTHER
Collaborators: name: Conselho Nacional de Desenvolvimento Científico e Tecnológico
First posted: 2019-06-13
Enrollment: 502
Sex: ALL
Minimum age (years): 9
Maximum age (years): 24
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: 502 children born from a HIV infected mother, divided in the following groups:

1. 251 HIV infected children, divided in the following subgroups:

   1. 9-15 months old;
   2. 16-21 months old;
   3. 22-24 months old
2. 251 HIV non infected children, divided in the following subgroups:

   1. 9-15 months old;
   2. 16-21 months old;
   3. 22-24 months old

Brief summary: Antiretroviral therapy of the mother and of the newborn associated with alternative schemes of breastfeeding can reduce these transmission rates to 1%. The diagnosis of HIV infection in newborns is based on PCR for detection of viral genetic material, a procedure that is expensive and of complex logistics. Tests based on detection of antibodies are faster and cheaper but cannot distinguish infected child or maternal antibodies passed to the fetus through the placenta. Nevertheless, the so-called rapid tests have been implemented in the network of health services because of their simplicity and performance comparable to conventional tests. DPP HIV 1/2 test, produced by Bio-Manguinos/Fiocruz, usage is limited by the manufacturer to over 24 months of age children, though the guidelines control programs already recommend the use from 18 months in Brazil and 9 months in other countries. Data on the accuracy of the rapid test under 24 months of age are scarce. This proposal aims to assess the performance of rapid tests produced by Bio-Manguinhos in diagnostic protocols for HIV infection in children 9-24 months old, in order to obtain empirical data to support the current recommendations on rapid tests, particularly in countries with limited access to tests that require specialized laboratories. The validation of rapid HIV testing in other age groups is a requirement of the national regulatory authorities, and has important implications for programs to control HIV-AIDS in populations from countries with limited access to specialized laboratory resources. The use of the rapid test can also represent a significant reduction in costs, as it allows limiting the use of molecular tests to complex and expensive confirmation cases.

Detailed description: It concerns a study with a sample composed of children born from HIV positive mothers, age between 9 and 24 months old, with confirmed or discarded infection for HIV determined by molecular testing. Samples from the volunteers will be subjected to rapid tests and serological and molecular reference tests.

After obtaining consent from the child's guardian,a brief interview will take place with completing the questionnaire of inclusion in the research. Then, the collection of fluid in the oral cavity as well as the fingerstick puncture will be conducted for the HIV rapid tests procedures.

The results of the rapid tests will be compared with the ones from the molecular testing and the concordance will be determined for each age group separately.

The study has being conducted by four clinical research sites at Brazil, distributed in three different states, and a clinical research site at Tanzânia: Instituto Fernandes Figueira (IFF - Fiocruz) at Rio de Janeiro; Hospital Geral de Nova Iguaçu (HGNI) at Rio de Janeiro, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado (FMT-HVD) at Amazonas; Secretaria de Estado de Saúde Pública do Pará (URES - Materno Infantil - UREMIA) at Pará and National Institute for Medical Research (NIMR) at Tanga in Tanzania.

Eligibility criteria: Inclusion Criteria:

Children must be born from a HIV infected mother; Molecular diagnostic tests available.

Exclusion Criteria:

Not applicable

Primary outcomes:
measure: Efficacy of the Bio-Manguinhos / Fiocruz Rapid DPP® HIV-1/2 Immunoblot
timeFrame: Day 1
Secondary outcomes:
measure: Efficacy of the Bio-Manguinhos / Fiocruz HIV-1/2 rapid serum screening test
timeFrame: Day 1
measure: Efficacy of the rapid Oral Fluid test HIV- 1/2 Bio- Manguinhos
timeFrame: Day 1
measure: Variations in the accuracy of rapid tests
timeFrame: Day 1
Other outcomes:
Locations:
city: Rio De Janeiro
country: Brazil
facility: Assessoria Clinica / Bio-Manguinhos / Fiocruz
Study officials:
affiliation: Escola Nacional de Saúde Pública - ENSP/Fiocruz
name: Luiz Antonio B Camacho, DrPH
role: PRINCIPAL_INVESTIGATOR
References: